CBL-514 and GLP-1 Drugs: Can Removing Fat Cells Limit Weight Regain?

Two trials define the problem. In the STEP 1 extension, people who stopped semaglutide regained about two-thirds of their prior weight loss within a year. In SURMOUNT-4, participants switched from tirzepatide to placebo after 36 weeks regained 14.0% of body weight, while those who continued lost a further 5.5%. In both, much of the effect depended on staying on the drug.

Several mechanisms contribute, from appetite returning to adaptive changes in energy expenditure. One of them is structural: weight loss through calorie restriction mostly makes fat cells smaller rather than fewer, which leaves the storage capacity in place.

A widely cited 2008 study in Nature used carbon-14 dating of adipocyte DNA to show that fat-cell number in adults is largely fixed after adolescence and stays constant even after marked weight loss, with roughly a tenth of fat cells replaced each year. Incretin drugs work on this system through intake: fat cells release stored lipid and shrink, but they remain.

CBL-514 targets the other variable. By inducing apoptosis, it is designed to reduce the number of adipocytes in the treated area. Caliway's hypothesis is that fewer fat cells means less capacity to refill once an incretin drug is withdrawn. It is a plausible idea – and so far an untested one in humans.

All four sets of results come from Caliway's announcements and conference abstracts. Rodent adipose tissue differs from human adipose tissue in distribution and turnover, and a systemic effect seen in a small animal treated over a large share of its body surface may not scale to a locally injected human abdomen.

In August 2026 the FDA cleared the IND for CBL-0201WR, a Phase 2 trial combining CBL-514 with tirzepatide. According to Caliway it will enrol about 120 participants at 10 US sites.

• Primary endpoint: MRI-measured abdominal subcutaneous fat volume four weeks after treatment is discontinued.
• Exploratory endpoints: body weight, visceral fat, body composition and HOMA-IR (an index of insulin resistance).

The design matters for interpretation. The primary endpoint measures fat volume in the treated region, not weight regain, which sits among the exploratory endpoints. A positive result would show that CBL-514 adds local fat reduction to tirzepatide; it would not by itself show that regain is prevented. That question needs longer follow-up after the incretin is stopped.

The OI26 study added eloralintide, Eli Lilly's amylin receptor agonist, which is being studied alone and together with tirzepatide. Amylin agonists act on satiety and gastric emptying, like GLP-1 drugs from a different angle. By testing CBL-514 next to both classes, Caliway is positioning it as an add-on to whichever appetite-based therapy becomes standard, not as a competitor to them.

• Translation: whether rodent regain data carry over to humans at all.
• Scale: how much of a person's total fat-cell number a local injection can remove, and whether that is enough to change whole-body regain.
• Durability: whether removed fat cells are replaced over time by new adipocytes.
• Visceral fat: how a subcutaneous injection would reduce visceral fat, a claim that so far rests on unpublished MRI analyses.
• Safety of the combination: CBL-0201WR is the first controlled data on co-administration in humans.

That has not been shown in humans. Caliway's animal studies report less regain with the combination, and the first human combination trial (CBL-0201WR) has been cleared, but its primary endpoint is local fat volume, not regain.

In company-reported animal studies: tirzepatide, semaglutide and eloralintide. In humans, the only cleared combination trial uses tirzepatide.

Fat-cell number in adults is largely fixed, and weight loss mostly shrinks existing cells. The hypothesis is that fewer fat cells leave less capacity to refill after treatment ends. It remains unproven in humans.

Not primarily. Its Phase 3 programme targets local abdominal fat reduction. Use alongside weight-management drugs is an exploratory Phase 2 programme.

Eloralintide is an investigational amylin receptor agonist from Eli Lilly, studied alone and in combination with tirzepatide for obesity.